Anticancer agent CHS-828 inhibits cellular synthesis of NAD.

Malignant cells display increased demands for energy production and DNA repair. Nicotinamide adenine dinucleotide (NAD) is required for both processes and is also continuously degraded by cellular enzymes. Nicotinamide phosphoribosyltransferase (Nampt) is a crucial factor in the resynthesis of NAD, and thus in cancer cell survival. Here, we establish the cytotoxic mechanism of action of the small molecule inhibitor CHS-828 to result from impaired synthesis of NAD. Initially, we detected cross-resistance in cells between CHS-828 and a known inhibitor of Nampt, FK866, a compound of a structurally different class. We then showed that nicotinamide protects against CHS-828-mediated cytotoxicity. Finally, we observed that treatment with CHS-828 depletes cellular NAD levels in sensitive cancer cells. In conclusion, these results strongly suggest that, like FK866, CHS-828 kills cancer cells by depleting NAD.

[1]  G. Hageman,et al.  Poly(ADP-ribose) polymerase-1 mediated caspase-independent cell death after ischemia/reperfusion. , 2005, Free radical biology & medicine.

[2]  T. Dawson,et al.  Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor , 2002, Science.

[3]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[4]  L. de Leij,et al.  Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. , 1985, Cancer research.

[5]  S. Imai,et al.  The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals , 2007, Current opinion in gastroenterology.

[6]  E. Verdin,et al.  Sirtuins: critical regulators at the crossroads between cancer and aging , 2007, Oncogene.

[7]  Max Hasmann,et al.  FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. , 2003, Cancer research.

[8]  L. Binderup,et al.  Early stimulation of acidification rate by novel cytotoxic pyridyl cyanoguanidines in human tumor cells: comparison with m-iodobenzylguanidine. , 2000, Biochemical pharmacology.

[9]  L. Binderup,et al.  Novel cyanoguanidines with potent oral antitumour activity , 1997 .

[10]  Mahasti Saghatchian,et al.  Molecular targets and cancer therapeutics. , 2007, European journal of cancer.

[11]  L. Binderup,et al.  Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828 , 2004, Anti-cancer drugs.

[12]  G. de Murcia,et al.  The PARP superfamily , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[13]  H. Hansen,et al.  Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. , 1993, British Journal of Cancer.

[14]  J. Khan,et al.  Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents , 2006, Nature Structural &Molecular Biology.

[15]  L. Guarente,et al.  Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. , 2006, Genes & development.

[16]  R. Stierum,et al.  Niacin, poly(ADP-ribose) polymerase-1 and genomic stability. , 2001, Mutation research.

[17]  L. Binderup,et al.  Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells. , 2001, European journal of cancer.

[18]  P. Pedersen.  The cancer cell’s “power plants” as promising therapeutic targets: An overview , 2007, Journal of bioenergetics and biomembranes.

[19]  R. Larsson,et al.  Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. , 2001, Biochemical pharmacology.

[20]  A. Bürkle,et al.  Poly(ADP‐ribosyl)ation inhibitors: Promising drug candidates for a wide variety of pathophysiologic conditions , 2004, International journal of cancer.

[21]  R. Larsson,et al.  The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro–from cytotoxic synergy to complete inhibition of apoptosis , 2002, British journal of pharmacology.

[22]  M. Madsen,et al.  Anticancer agent CHS 828 suppresses nuclear factor‐κB activity in cancer cells through downregulation of IKK activity , 2004, International Journal of Cancer.

[23]  R. Larsson,et al.  Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells. , 2002, Biochemical Pharmacology.

[24]  David T. Smith.  Niacin , 1943, Reactions Weekly.

[25]  L. Binderup,et al.  Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells. , 2001, European journal of pharmacology.

[26]  C. M. Hansen,et al.  Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro. , 2000, Anticancer research.

[27]  F H Dost,et al.  Was ist Pharmakokinetik?* , 1967 .

[28]  G. Poirier,et al.  Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. , 1999, The Biochemical journal.

[29]  M. Karlsson,et al.  CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome. , 2006, Anticancer research.

[30]  R. Frye,et al.  Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. , 1999, Biochemical and biophysical research communications.

[31]  T. Skov,et al.  CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. , 1999, Cancer research.

[32]  Chris Twelves,et al.  Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. , 2005, European journal of cancer.

[33]  L. Saltz,et al.  The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor , 2008, Investigational New Drugs.

[34]  M. Noda,et al.  Enhancement of poly‐adenosine diphosphate‐ribosylation in human hepatocellular carcinoma , 2000, Journal of gastroenterology and hepatology.

[35]  H. Hansen,et al.  Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. , 1993, Biochemical pharmacology.

[36]  R. Larsson,et al.  Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cells. , 2002, Anticancer research.